Bio Design Lab (BDL) aims to develop gene, cell, immuno-therapies. Lack of efficient and safe vectors has hampered the development of the next-generation therapies. We are currently focusing on advancing retroviral and lentiviral vectors in terms of transduction efficiency and safety. By applying various genetic engineering approaches, we have been able to greatly enhance the transduction efficiency and reduce tumorigenicity of the key viral vectors up to multiple folds. In addition, BDL develops various additional genetic platforms to fuel the advances in gene-, cell-, immune-therapies.
Product Efficiency
Bio Design lab has developed various technologies to enhance treatment efficiencies including vectors with stronger gene expression, vectors with larger gene loading capacities, and vectors for mitochondria,
Product Safety
Scientifically, retro/lentiviral vectors are known to favor insertions into dangerous sites such as transcription start sites and oncogenic sites that can cause cancer. Bio Design Lab has developed very safe retro/lentiviral vectors by minimizing such insertion preferences showing no risks for clonal expansions
Product Productivity
Bio Design Lab has developed various technologies to improve viral vector productivity and has secured a vector platform that assures significantly higher productivity.
WE DEVELOP VIRAL VECTORS FOR SAFETY AND EFFICACY
Bio Design Lab is a biotech company that has developed platforms for the next generation of safer and more efficacious viral vectors. Viral vectors act as vehicles which transport genetic cargo into cells, and once inside can release it and enable the production of therapeutic proteins. We have redesigned two types of viral vectors, retroviral and lentiviral vectors, to significantly increase their safety and improve their gene delivery efficiencies.



